FDA Approves Safer Dosing Regimen for Eli Lilly’s Alzheimer’s Drug Kisunla

Eli Lilly shares gained 1.19% to $786.92 after regulators approved an updated label for its Alzheimer's treatment. The new titration protocol reduces brain swelling risks by up to 41% while preserving therapeutic benefits, according to Phase 3 trial data.

The modified dosing schedule delays administration of one vial until the third infusion, maintaining cumulative drug exposure while cutting ARIA-E incidence from 24% to 14% at six months. Safety improvements come without compromising Kisunla's ability to slow cognitive decline in early-stage patients.

Lilly's stock has quadrupled since 2019 despite recent volatility, reflecting investor confidence in the pharma giant's neurology pipeline. The label update strengthens Kisunla's competitive position against rival amyloid-targeting therapies.